Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

M. Moehler, J. Heo, H. C. Lee, W. Y. Tak, Y. Chao, S. W. Paik, H. J. Yim, K. S. Byun, A. Baron, G. Ungerechts, D. Jonker, L. Ruo, M. Cho, A. Kaubisch, H. Wege, P. Merle, O. Ebert, F. Habersetzer, J. F. Blanc, Olivier RosmorducR. Lencioni, R. Patt, A. M. Leen, F. Foerster, M. Homerin, N. Stojkowitz, M. Lusky, J. M. Limacher, M. Hennequi, N. Gaspar, B. McFadden, N. De Silva, D. Shen, A. Pelusio, D. H. Kirn, C. J. Breitbach, J. M. Burke

Research output: Contribution to journal › Article › peer-review

81 Scopus citations

Fingerprint

Dive into the research topics of 'Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)'. Together they form a unique fingerprint.

Medicine & Life Sciences